Objectives To analyze the efficacy and safety of auricular acupuncture (AA) in patients with cognitive impairment and dementia. Methods Twelve electronic databases were searched for randomized controlled trials evaluating effects of AA in patients with cognitive impairment and/or dementia, from their inception to August 2017. The primary outcome was cognitive function, and secondary outcomes were self-care ability, quality of life, clinical efficacy rate, and incidences of adverse events. Results Nine studies were included, and five involving 677 participants were analyzed quantitatively. Compared with Western medications (WM), AA had mixed effects on cognitive functions (Mini-Mental State Examination [MMSE], mean difference [MD] 0.73, 95% confidence interval [CI] −0.02 to 1.48; Hierarchic Dementia Scale [HDS], MD 2.21, 95% CI 1.09 to 3.33); there was no significant improvement in the activities of daily living (ADL) score (MD 0.20, 95% CI −3.51 to 3.91) in patients with vascular dementia (VD). Compared to WM, AA combined with WM showed better clinical efficacy rate (risk ratio [RR] 1.42, 95% CI 1.06 to 1.91) in patients with VD; there was no significant improvement in cognitive functions (MMSE, MD 0.97, 95% CI −0.44 to 2.38; Montreal Cognitive Assessment [MoCA], MD 0.22, 95% CI −1.83 to 2.27) in patients with mild cognitive impairment (MCI). Compared to herbal medicine (HM), AA plus HM showed significant improvements in cognitive function (MMSE, MD 1.31, 95% CI 0.13 to 2.49) in patients with MCI and patients with vascular cognitive impairment, no dementia (VCIND) and in ADL score (MD −6.70, 95% CI −8.78 to −4.62) in patients with MCI. No adverse event associated with AA was reported. Conclusion The evidence reveals mixed efficacy of AA in patients with cognitive impairment and/or dementia. However, the results were inconclusive because of the small number and poor methodological quality of the included studies.

Electron-transfer (ET) theory describes rates in terms of nuclear-reorganization ( ) and electronic-coupling (//AB) parameters.1 These parameters are most directly determined from the driving-force dependence of the ET rate (ideally at high driving forces in the neighborhood of X).2 Remarkably slow ET rates have been observed at low driving forces (-(7°< 0.3 eV) in certain iron-sulfur3 and blue copper proteins,4 and at high driving forces in Ru(bpy)2L(His-33) (bpy = 2,2'-bipyridine; L = imidazole, pyridine, H20; His = histidine) derivatives of cytochrome c (cyt c).5 Since the latter results conflict sharply with the much faster ET rates reported for Ru-modified Zn-substituted cytochrome c (Ru-Zn-cyt c)2,6 and Ru(bpy)2(dcbpy)-labeled ferrocytochrome c (dcbpy = dicarboxybipyridine),7,8 we have determined the Ru(bpy)2L(His-33)-cyt c kinetics by using a novel flash-quench method that allows the observation of rates over an extremely wide range.9"11The rate of intramolecular oxidation of horse heart ferrocytochrome c by Ru(bpy)2(im)(His-33)3+ (im = imidazole) 12,13

No abstract

No abstract

In many studies, resveratrol has been shown to have a chemopreventive effect in various types of cancer cells. However, the biological activity of resveratrol is limited by its photosensitivity and metabolic instability. This study investigated the effects of a novel analogue of resveratrol, HS-1793, on the expression of HIF-1α and vascular endothelial growth factor (VEGF) in PC-3 human prostate cancer cells. Hypoxic condition induced HIF-1α protein level in PC-3 cells in a time-dependent manner, and treatment with HS-1793 markedly decreased HIF-1α expression levels. HS-1793 also inhibited VEGF level. Mechanistically, HS-1793 inhibited HIF-1α and VEGF expression through multiple mechanisms. Firstly, HS-1793 inhibited phosphorylation of PI3K and Akt in PC-3 cells. Furthermore, HS-1793 substantially induced HIF-1α protein degradation through the proteasome pathway. Finally, HS-1793 inhibited hypoxia-induced PC-3 cell migration. These data suggest that HS-1793 may inhibit human prostate cancer progression and angiogenesis by inhibiting the expression of HIF-1α and VEGF. Moreover, HS-1793 showed more potent effects than resveratrol on the cytotoxic effects on PC-3 cells. Taken together, these results implied that HS-1793, a novel analogue of resveratrol, may be a new potent chemopreventive agent against human prostate cancer cells.

No abstract

No abstract

No abstract